Keywords
Pathological diagnosis
Immunohistochemical detection
Submitted : 2024-06-10
Accepted : 2024-06-25
Published : 2024-07-10
Abstract
Objective: To investigate the clinical value of immunohistochemistry (IHC) detection in the pathological diagnosis of breast cancer. Methods: Eighty breast cancer patients admitted to Baoding No. 1 Central Hospital from June 2022 to June 2023 were selected as study subjects. The samples were divided into a positive group (40 cases) and a negative group (40 cases) according to ER and PR test results. Immunohistochemistry was performed on all patients to compare the differences between the two groups in C-erbB-2 positive expression and axillary lymph node metastasis. Results: The positive expression rate of C-erbB-2 in the positive group (35.00%) was significantly lower than that in the negative group (80.00%), with a highly significant difference (P < 0.001). The axillary lymph node metastasis rate in the positive group (40.00%) was significantly lower than that in the negative group (75.00%), with a significant difference (P < 0.05). Conclusion: Immunohistochemical detection in breast cancer pathology enhances diagnostic accuracy, predicts prognosis, and supports personalized treatment by identifying ER, PR, and C-erbB-2. It is worth being widely adopted in clinical practice.
References
Li J, Shi Z, Hou Y, et al., 2019, Clinical, Pathological and Immunohistochemical Basis of Ultrasound Features in Invasive Triple-Negative Breast Cancer. Chinese Journal of Cancer, 29(1): 37–44.
Wang L, Ren F, Fan Y, et al., 2023, Correlation Analysis of VEGF, ALDH1, BCRP Expression in Breast Cancer Tissues and Pathological Features of Breast Cancer. Clinical Medical Engineering, 30(5): 721–722.
Chen Y, Li H, Wang C, 2022, Diagnostic Efficacy of Ultrasound Elastography and Ultrasonography for Breast Cancer and Its Correlation with Immunohistochemical Parameters. Journal of Clinical and Pathological Sciences, 42(10): 2420–2426.
Oncology Committee of Chinese Association of Integrative Medicine, Integrative Medicine Committee of Beijing Breast Disease Prevention and Treatment Association, Beijing Integrative Medicine Chronic Disease Prevention and Control, et al., 2021, Consensus on Diagnosis and Treatment of Breast Cancer with Integration of Traditional and Western Medicine. Chinese Journal of Frontiers of Medicinal Science (Electronic Edition), 13(7): 44–64.
Huang Q, Huang Y, Li M, et al., 2919, Analysis of the Correlation between High Expression of Vascular Endothelial Growth Factor (VEGF) and Low Expression of Platelet-Responsive Protein 1 (TSP-1) and the Prognosis of Breast Cancer Patients. Journal of Cellular and Molecular Immunology, 35(9): 828–831.
Li W, Bai J, Xie X, et al., 2020, Effect of Neutrophil-to-Lymphocyte Ratio on Clinical Prognosis of Triple-Negative Breast Cancer and with Ki-67 Expression. Modern Preventive Medicine, 47(12): 2287–2291 + 2304.
Wei J, Xing X, Wang F, et al., 2022, Comparison of the Value of Immunocytochemical P16/Ki-67 Double Staining, P16INK4alpha Single Staining and High-Risk Human Papillomavirus Test for Screening High-Grade Cervical Lesions. Oncology Research and Clinics, 34(3): 180–183.
Wang Z, Zhou H, Wu H, et al., 2020, Impact of Epidermal Growth Factor Receptor Protein and Clinicopathological Features on the Effect and Prognosis of Neoadjuvant Chemotherapy for Breast Cancer. Hebei Medicine, 42(3): 325–329.
Yu X, Qin H, 2018, Expression of ER, PR, C-erbB-2, P53, and Ki-67 in Breast Cancer Tissues and Correlation with Their Clinicopathological Features. Journal of Practical Cancer, 33(1): 39–42.